Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bearish -15

Moderna stock trades at EUR 172.26 ahead of melanoma data

Analyst downgrade Clinical trial results Company update AI-generated analysis

📅 Moderna is set to present Phase 3 melanoma data for intismeran autogene at the ESMO Congress on October 24, 2026.

💊 The central study evaluates intismeran combined with pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma patients.

📉 Q2 revenue fell sharply to USD 0.1 billion from USD 0.4 billion in Q1, representing a significant sequential contraction.

💸 The company reported a GAAP net loss of USD 0.8 billion and an EPS of minus USD 1.97 for the quarter ended June 30, 2026.

🎯 UBS reiterated a Neutral rating with a USD 150.00 price target, expecting a hazard ratio of 0.65 or better for approval.

📉 Bernstein SocGen Group maintains a Market Perform rating but set a lower USD 45.00 price target ahead of the data.

📊 Moderna stock traded at EUR 172.26 on September 29, 2026, down 0.77 percent versus the prior close.

💰 The company holds a market capitalization of USD 78.3 billion with a 52-week range between USD 22.28 and USD 202.67.

🎤 An investor webcast is scheduled for October 24 at 7:00 p.m. CEST to discuss the upcoming clinical readout.

Bullish Signals
  • Moderna has secured acceptance for three abstracts regarding its intismeran autogene candidate for presentation at the prestigious ESMO Congress.
  • The company is hosting a dedicated investor webcast on October 24 to provide a clear update on the pivotal melanoma Phase 3 study results.
Risk Factors
  • Q2 revenue dropped sharply to USD 0.1 billion from USD 0.4 billion in the previous quarter, indicating significant sequential contraction.
  • The company reported a substantial GAAP net loss of USD 0.8 billion and an EPS of minus USD 1.97 for the quarter ended June 30, 2026.
  • Analysts are demanding a hazard ratio of 0.65 or better (35 percent risk reduction) to justify current valuations, creating high pressure on the upcoming data.
Full Analysis
Moderna Inc. (MRNA) is approaching a critical oncology milestone with Phase 3 melanoma data for its intismeran autogene candidate scheduled for presentation at the ESMO Congress on October 24, 2026. The company has received acceptance for three abstracts, with the central presentation focusing on a study of intismeran combined with pembrolizumab versus pembrolizumab alone in resected stage IIB-IV melanoma patients. Following the recent quarter ended June 30, 2026, Moderna reported a sharp sequential contraction in revenue, falling to USD 0.1 billion from USD 0.4 billion in the prior quarter. The company also posted a GAAP net loss of USD 0.8 billion and an EPS of minus USD 1.97, highlighting its continued dependence on successful product launches and pipeline progress rather than current earnings power. Wall Street analysts are closely watching the upcoming data for specific efficacy metrics. UBS reiterated a Neutral rating with a USD 150.00 price target, noting the market expects a hazard ratio of 0.65 or better (equivalent to a 35 percent risk reduction). Conversely, Bernstein SocGen Group maintains a Market Perform rating but has set a significantly lower USD 45.00 price target, underscoring the high valuation sensitivity to the melanoma program's outcome. Moderna stock was trading at EUR 172.26 on September 29, 2026, reflecting a slight decline of 0.77 percent against the prior close. The company remains listed on Nasdaq with a market capitalization of USD 78.3 billion and a 52-week trading range spanning from USD 22.28 to USD 202.67, as investors await the investor webcast scheduled for October 24 at 7:00 p.m. CEST.